Advanced search
Publication Cover
Bioengineered Volume 13, 2022 - Issue 3
Submit an article Journal homepage
2,618
Views
5
CrossRef citations to date
0
Altmetric
Research Paper

Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro

Jingquan Jia Department of Pathophysiology, Changzhi Medical College, Changzhi, Shanxi, ChinaCorrespondence[email protected]
View further author information
,
Ming Fengb Department of Neurosurgery, Changzhi People’s Hospital, Changzhi, Shanxi, ChinaView further author information
,
Yan Huangc Department of Biochemistry, Changzhi Medical College, Changzhi, Shanxi, ChinaView further author information
&
Xiaohong Niud Department of Endocrinology, The Heji Affiliated Hospital of Changzhi Medical College, Changzhi, Shanxi, ChinaView further author information
Pages 5091-5102 | Received 09 Nov 2021, Accepted 26 Jan 2022, Published online: 14 Feb 2022

Reprints and Permissions

This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article in part or whole.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.